LFCR

Lifecore Biomedical, Inc. NASDAQ

Healthcare ·Drug Manufacturers - Specialty & Generic ·US · lifecore.com

$5.13

After hrs $5.16 +0.00%

Mkt Cap $192.3M

52w Low $3.63 28.0% of range 52w High $8.98

50d MA $5.36 200d MA $6.98

P/E (TTM) -4.1x

EV/EBITDA -40.5x

P/B 137.0x

Debt/Equity 97.9x

ROE 308.2%

P/FCF -17.2x

RSI (14) —

ATR (14) —

Beta 0.88

50d MA $5.36

200d MA $6.98

Avg Volume 323.2K

About

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. It operates through Lifecore, Curation Foods, and Other segments. The Lifecore segment engages in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and…

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Mar 16, 2026	AMC	-0.27	-0.16	+40.7%	4.37	+0.2%	-0.2%	-5.0%	-7.1%	-8.0%	-7.3%	—
Nov 6, 2025	AMC	-0.30	-0.29	+3.3%	6.62	-0.5%	+3.5%	+10.1%	+16.9%	+24.2%	+19.2%	—
Aug 7, 2025	AMC	-0.09	-0.10	-11.1%	7.76	-3.4%	-6.7%	-7.0%	-1.7%	-0.3%	-4.4%	—
Apr 3, 2025	AMC	-0.14	-0.19	-35.7%	6.81	-7.5%	-22.3%	-25.1%	-23.5%	-8.5%	-16.0%	—
Jan 2, 2025	AMC	-0.27	-0.25	+7.4%	6.66	+6.5%	+14.4%	+3.2%	-11.3%	-12.9%	-5.6%	—
Aug 26, 2024	AMC	-0.12	-0.15	-25.0%	6.34	-8.7%	-25.2%	-37.4%	-39.7%	-30.9%	-31.1%	—
Aug 9, 2024	AMC	-0.12	-0.41	-241.7%	5.01	-0.2%	+8.4%	+20.6%	+16.0%	+19.4%	+14.8%	—
May 22, 2024	AMC	-0.23	0.43	+285.7%	5.83	+1.2%	-2.4%	-3.6%	-4.3%	-1.9%	-0.9%	—
Dec 29, 2023	AMC	-0.23	0.39	+269.7%	6.19	-0.6%	+3.1%	+2.6%	+2.1%	+14.9%	+22.8%	—
Aug 31, 2023	AMC	-0.07	-0.89	-1171.4%	8.00	+0.0%	-1.6%	-2.1%	-2.1%	-3.1%	-6.4%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Apr 29	Barrington Research	Maintains	Outperform → Outperform	—	$5.12	$5.13	+0.2%	-3.5%	-1.0%	+2.7%	—	—
Mar 27	Barrington Research	Maintains	Outperform → Outperform	—	$3.87	$3.84	-0.8%	-5.4%	-2.1%	-3.9%	-0.8%	-0.8%
Mar 24	Barrington Research	Maintains	Outperform → Outperform	—	$4.05	$4.00	-1.2%	-1.2%	+3.5%	-4.4%	-9.6%	-6.4%
Mar 17	Barrington Research	Upgrade	Market Perform → Outperform	—	$4.37	$4.38	+0.2%	-0.2%	-5.0%	-7.1%	-8.0%	-7.3%
Jan 3	Stephens & Co.	Maintains	Equal Weight → Equal Weight	—	$6.66	$7.09	+6.5%	+14.4%	+3.2%	-11.3%	-12.9%	-5.6%
Nov 22	Craig-Hallum	Maintains	Buy → Buy	—	$6.98	$7.14	+2.3%	+4.7%	+6.9%	+6.6%	+7.4%	+6.2%
Aug 28	Barrington Research	Downgrade	Outperform → Market Perform	—	$4.74	$4.60	-3.0%	-16.2%	-19.4%	-7.6%	-7.8%	-11.0%
Sep 1	Barrington Research	Maintains	Outperform → Outperform	—	$8.00	$8.00	+0.0%	-1.6%	-2.1%	-2.1%	-3.1%	-6.4%
Sep 1	Stephens & Co.	Maintains	Equal Weight → Equal Weight	—	$8.00	$8.00	+0.0%	-1.6%	-2.1%	-2.1%	-3.1%	-6.4%
Jun 2	Barrington Research	Maintains	Outperform → Outperform	—	$8.25	$8.66	+5.0%	-1.2%	+1.3%	+3.0%	+1.1%	+1.5%
May 24	Barrington Research	Maintains	Outperform → Outperform	—	$8.05	$7.83	-2.7%	+3.9%	+3.7%	-1.4%	-0.5%	+1.7%
Mar 21	Barrington Research	Maintains	Outperform → Outperform	—	$3.10	$2.97	-4.2%	+4.8%	+5.0%	-1.9%	+0.6%	+3.5%
Mar 20	Barrington Research	Maintains	Outperform → Outperform	—	$1.67	$1.81	+8.4%	+85.6%	+94.6%	+94.9%	+82.0%	+86.8%
Mar 20	Stephens & Co.	Downgrade	Overweight → Equal Weight	—	$1.67	$1.81	+8.4%	+85.6%	+94.6%	+94.9%	+82.0%	+86.8%
Mar 17	Stephens & Co.	Maintains	Overweight → Overweight	—	$5.11	$3.30	-35.4%	-67.3%	-39.3%	-36.4%	-36.3%	-40.5%
Oct 6	Barrington Research	Maintains	Outperform → Outperform	—	$8.70	$8.69	-0.1%	+0.1%	-5.3%	-7.5%	-5.4%	-7.4%
Aug 10	Barrington Research	Upgrade	Market Perform → Outperform	—	$10.80	$10.96	+1.5%	+2.0%	+4.7%	+4.0%	+7.1%	+7.0%
Jul 20	Stephens & Co.	Maintains	Overweight → Overweight	—	$10.07	$10.50	+4.3%	+6.7%	+4.2%	+2.2%	+2.7%	+2.3%
Apr 6	Barrington Research	Downgrade	Outperform → Perform	—	$11.33	$10.21	-9.9%	-6.0%	-5.3%	-7.3%	-7.1%	-8.1%
Apr 5	Barrington Research	Downgrade	Outperform → Market Perform	—	$11.61	$11.69	+0.7%	-2.4%	-8.3%	-7.6%	-9.6%	-9.3%
Oct 3	Roth Capital	Maintains	Buy → Buy	—	—	—	—	—	—	—	—	—
Jul 29	Roth Capital	Maintains	Buy → Buy	—	$12.44	$12.40	-0.3%	-9.1%	-12.1%	-14.5%	-13.2%	-15.4%
Jun 1	Barrington Research	Upgrade	Market Perform → Outperform	—	$11.97	$11.98	+0.1%	-2.8%	+3.9%	+2.8%	+6.5%	+6.8%
Apr 8	Roth Capital	Maintains	Buy → Buy	—	$10.95	$9.38	-14.3%	-8.5%	-9.5%	-8.1%	-5.0%	-3.7%
Jan 5	Barrington Research	Downgrade	Outperform → Market Perform	—	—	—	—	—	—	—	—	—
Apr 7	Roth Capital	Downgrade	Buy → Neutral	—	—	—	—	—	—	—	—	—
Apr 1	Imperial Capital	Maintains	Outperform → Outperform	—	$13.95	$13.70	-1.8%	+2.4%	+3.9%	+5.9%	+4.9%	+3.7%
Oct 8	Feltl & Co.	Downgrade	Buy → Hold	—	$11.32	$11.30	-0.2%	+1.9%	-1.6%	-1.5%	+0.7%	+1.1%
Apr 13	Northland Capital Markets	Maintains	Outperform → Outperform	—	—	—	—	—	—	—	—	—

Recent Filings

8-K · 7.01 ! Medium

Unknown — 8-K 7.01: Regulation FD Disclosure

Lifecore Biomedical disclosed material information via press release on March 16, 2026, potentially signaling significant news about operations, partnerships, or financials that could materially impact LFCR's stock valuation and investor positioning.

Mar 16

8-K

Lifecore Biomedical, Inc. -- 8-K Filing

Lifecore Biomedical has announced a shareholder proposal deadline of March 16, 2026, requiring submissions to comply with SEC regulations and company bylaws.

Mar 5

Data updated apr 25, 2026 6:55pm · Source: massive.com